Elisenda Alsina-Sanchís1,2, Yaiza García-Ibáñez1,2, Ana M Figueiredo1,3,2, Carla Riera-Domingo1,2, Agnès Figueras1,2, Xavier Matias-Guiu2,4,5,6, Oriol Casanovas1,2, Luisa M Botella7, Miquel A Pujana1,2, Antoni Riera-Mestre8,9, Mariona Graupera10,3,11, Francesc Viñals10,2,12. 1. From the Program Against Cancer Therapeutic Resistance, Institut Català d'Oncologia, Hospital Duran i Reynals (E.A.-S., Y.G.-I., A.M.F., C.R.-D., A.F., O.C., M.A.P., M.G., F.V.). 2. Institut d'Investigació Biomèdica de Bellvitge, Spain (E.A.-S., Y.G.-I., A.M.F., C.R.-D., A.F., X.M.-G., O.C., M.A.P., F.V.). 3. Vascular Signaling Laboratory, Institut d´Investigació Biomèdica de Bellvitge (A.M.F., M.G.), L'Hospitalet de Llobregat, Barcelona, Spain. 4. Servei d'Anatomia Patològica (X.M.-G.). 5. Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, Spain; Hospital Universitari Arnau de Vilanova, Lleida, Spain (X.M.-G.). 6. Universitat de Lleida, Spain (X.M.-G.). 7. Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas, Madrid, Spain (L.M.B.). 8. HHT Unit, Internal Medicine Department (A.R.-M.). 9. Departament de Ciències Clíniques, Universitat de Barcelona, Spain (A.R.-M.). 10. From the Program Against Cancer Therapeutic Resistance, Institut Català d'Oncologia, Hospital Duran i Reynals (E.A.-S., Y.G.-I., A.M.F., C.R.-D., A.F., O.C., M.A.P., M.G., F.V.) fvinyals@iconcologia.net mgraupera@idibell.cat. 11. CIBERONC, Madrid, Spain (M.G.). 12. Departament de Ciències Fisiològiques, Campus de Bellvitge, Universitat de Barcelona, L'Hospitalet de Llobregat, Spain (F.V.).
Abstract
OBJECTIVE: ALK1 (activin-receptor like kinase 1) is an endothelial cell-restricted receptor with high affinity for BMP (bone morphogenetic protein) 9 TGF-β (transforming growth factor-β) family member. Loss-of-function mutations in ALK1 cause a subtype of hereditary hemorrhagic telangiectasia-a rare disease characterized by vasculature malformations. Therapeutic strategies are aimed at reducing potential complications because of vascular malformations, but currently, there is no curative treatment for hereditary hemorrhagic telangiectasia. APPROACH AND RESULTS: In this work, we report that a reduction in ALK1 gene dosage (heterozygous ALK1+/- mice) results in enhanced retinal endothelial cell proliferation and vascular hyperplasia at the sprouting front. We found that BMP9/ALK1 represses VEGF (vascular endothelial growth factor)-mediated PI3K (phosphatidylinositol 3-kinase) by promoting the activity of the PTEN (phosphatase and tensin homolog). Consequently, loss of ALK1 function in endothelial cells results in increased activity of the PI3K pathway. These results were confirmed in cutaneous telangiectasia biopsies of patients with hereditary hemorrhagic telangiectasia 2, in which we also detected an increase in endothelial cell proliferation linked to an increase on the PI3K pathway. In mice, genetic and pharmacological inhibition of PI3K is sufficient to abolish the vascular hyperplasia of ALK1+/- retinas and in turn normalize the vasculature. CONCLUSIONS: Overall, our results indicate that the BMP9/ALK1 hub critically mediates vascular quiescence by limiting PI3K signaling and suggest that PI3K inhibitors could be used as novel therapeutic agents to treat hereditary hemorrhagic telangiectasia.
OBJECTIVE:ALK1 (activin-receptor like kinase 1) is an endothelial cell-restricted receptor with high affinity for BMP (bone morphogenetic protein) 9 TGF-β (transforming growth factor-β) family member. Loss-of-function mutations in ALK1 cause a subtype of hereditary hemorrhagic telangiectasia-a rare disease characterized by vasculature malformations. Therapeutic strategies are aimed at reducing potential complications because of vascular malformations, but currently, there is no curative treatment for hereditary hemorrhagic telangiectasia. APPROACH AND RESULTS: In this work, we report that a reduction in ALK1 gene dosage (heterozygous ALK1+/- mice) results in enhanced retinal endothelial cell proliferation and vascular hyperplasia at the sprouting front. We found that BMP9/ALK1 represses VEGF (vascular endothelial growth factor)-mediated PI3K (phosphatidylinositol 3-kinase) by promoting the activity of the PTEN (phosphatase and tensin homolog). Consequently, loss of ALK1 function in endothelial cells results in increased activity of the PI3K pathway. These results were confirmed in cutaneous telangiectasia biopsies of patients with hereditary hemorrhagic telangiectasia 2, in which we also detected an increase in endothelial cell proliferation linked to an increase on the PI3K pathway. In mice, genetic and pharmacological inhibition of PI3K is sufficient to abolish the vascular hyperplasia of ALK1+/- retinas and in turn normalize the vasculature. CONCLUSIONS: Overall, our results indicate that the BMP9/ALK1 hub critically mediates vascular quiescence by limiting PI3K signaling and suggest that PI3K inhibitors could be used as novel therapeutic agents to treat hereditary hemorrhagic telangiectasia.
Authors: Piotr Kobialka; Helena Sabata; Sandra D Castillo; Mariona Graupera; Odena Vilalta; Leonor Gouveia; Ana Angulo-Urarte; Laia Muixí; Jasmina Zanoncello; Oscar Muñoz-Aznar; Nagore G Olaciregui; Lucia Fanlo; Anna Esteve-Codina; Cinzia Lavarino; Biola M Javierre; Veronica Celis; Carlota Rovira; Susana López-Fernández; Eulàlia Baselga; Jaume Mora Journal: EMBO Mol Med Date: 2022-06-13 Impact factor: 14.260
Authors: Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2019-12-23 Impact factor: 8.311
Authors: Maxim V Kuleshov; Zhuorui Xie; Alexandra B K London; Janice Yang; John Erol Evangelista; Alexander Lachmann; Ingrid Shu; Denis Torre; Avi Ma'ayan Journal: Nucleic Acids Res Date: 2021-07-02 Impact factor: 16.971
Authors: Qiuwang Zhang; Chenxi Wang; Anthony Cannavicci; Marie E Faughnan; Michael J B Kutryk Journal: Transl Res Date: 2021-04-22 Impact factor: 10.171
Authors: Antoni Riera-Mestre; José María Mora-Luján; Javier Trujillo-Santos; Jorge Del Toro; José Antonio Nieto; José María Pedrajas; Raquel López-Reyes; Silvia Soler; Aitor Ballaz; Pau Cerdà; Manel Monreal Journal: Orphanet J Rare Dis Date: 2019-08-09 Impact factor: 4.123
Authors: Yong Hwan Kim; Phuong-Nhung Vu; Se-Woon Choe; Chang-Jin Jeon; Helen M Arthur; Calvin P H Vary; Young Jae Lee; S Paul Oh Journal: Circ Res Date: 2020-07-31 Impact factor: 17.367